Solid Biosciences Inc.(SLDB)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Pending next ranking run
This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
SLDB Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Solid Biosciences Inc. (SLDB), a Healthcare sector company. SLDB is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q1 2026), Solid Biosciences Inc. reports net income of $-56.7M, free cash flow of $-47.4M. Top institutional holders of SLDB by reported 13-F value include PERCEPTIVE ADVISORS, Bain Capital Life Sciences Investors,, RA CAPITAL MANAGEMENT, L.P., based on the most recent SEC filings. SLDB trades on the Nasdaq exchange and files with the SEC under CIK 1707502. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SLDB daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Solid Biosciences Inc. directly from SEC EDGAR. Solid Biosciences Inc.'s 13F Pro composite quality score has ranged between 25 and 30 since 2023, currently 25.5 — a stable long-term trajectory across 8 quarterly and live scoring snapshots.
Net Income
Q1 2026
$-56.7M
Free Cash Flow
Q1 2026
$-47.4M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
Net Income
Operating Income
-38.1% YoYEPS (Diluted)
+35.0% YoYTotal Assets
+23.3% YoYOp. Cash Flow
-56.3% YoY| Metric | FY 2025 | FY 2024 | FY 2021 | FY 2020 | FY 2019 | FY 2017 |
|---|---|---|---|---|---|---|
| Revenue | — | — | $13.6M | $0.00 | $0.00 | $0.00 |
| Net Income | — | — | — | — | $-117.2M -120.4% | $-53.2M |
| Operating Income | $-179.2M -38.1% | $-129.7M -79.5% | $-72.3M +18.3% | $-88.4M +25.9% | $-119.3M -117.5% | $-54.9M |
| EPS (Diluted) | $-1.99 +35.0% | $-3.06 +39.6% | $-5.07 +80.1% | $-25.50 | — | — |
| Total Assets | $232.5M +23.3% | $188.7M -18.8% | $232.4M +35.8% | $171.2M +65.4% | $103.5M +35.8% | $76.2M |
| Operating Cash Flow | $-156.3M -56.3% | $-100.0M -28.6% | $-77.8M -37.4% | $-56.6M +39.0% | $-92.7M -114.5% | $-43.2M |
AI Insight: SLDB Ratio Trends
ROIC remains deeply negative across all periods, with no sustained recovery trajectory despite quarter-to-quarter volatility.
• ROIC deteriorated from -57.5% in Q2 2024 to -88.2% in Q3 2025, reflecting persistent value destruction.
• TTM ROIC of -52.5% as of Q1 2026 shows marginal improvement from Q3 2025 low, but remains severely negative.
⚠ Q3 2025 ROIC hit -88.2%, worst in dataset. Monitor whether Q1 2026 stabilization at -61.3% signals operational inflection or noise.
⚠ Absence of positive ROIC data across 9 periods suggests pre-revenue or development-stage dynamics; track when profitability inflects.
Get alerted when SLDB's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Solid Biosciences Inc. including:
Top Institutional Holders of SLDB
PERCEPTIVE ADVISORS LLC
$85.7M11,906,646 shBain Capital Life Sciences Investors, LLC
$70.6M9,808,819 shRA CAPITAL MANAGEMENT, L.P.
$67.2M9,339,978 shSiren, L.L.C.
$55.4M7,690,405 shVestal Point Capital, LP
$36.0M5,000,000 shBlackRock, Inc.
$35.7M4,958,354 shJANUS HENDERSON GROUP PLC
$28.9M4,010,695 shFMR LLC
$26.0M3,606,404 shDeep Track Capital, LP
$25.7M3,565,062 shARMISTICE CAPITAL, LLC
$23.0M3,200,000 sh
| Fund | Value | Shares |
|---|---|---|
| PERCEPTIVE ADVISORS LLC | $85.7M | 11,906,646 |
| Bain Capital Life Sciences Investors, LLC | $70.6M | 9,808,819 |
| RA CAPITAL MANAGEMENT, L.P. | $67.2M | 9,339,978 |
| Siren, L.L.C. | $55.4M | 7,690,405 |
| Vestal Point Capital, LP | $36.0M | 5,000,000 |
| BlackRock, Inc. | $35.7M | 4,958,354 |
| JANUS HENDERSON GROUP PLC | $28.9M | 4,010,695 |
| FMR LLC | $26.0M | 3,606,404 |
| Deep Track Capital, LP | $25.7M | 3,565,062 |
| ARMISTICE CAPITAL, LLC | $23.0M | 3,200,000 |
More Healthcare Companies
View all Healthcare →Put SLDB on your watchlist
Track score changes the day Solid Biosciences Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is SLDB a good stock to buy?
13F Pro's AI-powered analysis of Solid Biosciences Inc. (SLDB) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for SLDB are available on the SLDB stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own SLDB?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling SLDB. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Solid Biosciences Inc.'s investment landscape.